Woburn, Mass.-based GeneXP this week named a seven-person scientific advisory board including: David Evans, head of drug discovery for the Translational Genomics Research Institute; Geoff Ginsburg, vice president, molecular medicine and research strategy, Millennium; Glenn Hoke, president and chief science officer, Dyad Pharmaceuticals and former vice president of research and development, Gene Logic; Josh LaBaer, director, Harvard Institute of Proteomics, Harvard Medical School; John Quackenbush, investigator, The Institute for Genomic Research; and Ray Stoll, former director of toxicology and safety assessment, Boehringer Ingelheim.
Anthony Recupero has joined MaxCyte, a therapeutic gene transfer company based in Rockville, Md., as vice president for business development. He was previously senior director for business development at Gene Logic.
Karen Gibson has become senior vice president of information technology and chief information officer, and Nicolas Barthelemy has become senior vice president of global operations of Invitrogen. Gibson was previously vice president of global e-business and chief information officer at General Electric’s Medical Systems Information Technologies division. She holds an MBA from Ohio University and a BS in computer technology from Purdue. Barthelemy joins Invitrogen from Biogen, where he was vice president of manufacturing and general manager of the company’s Research Triangle Park site. He holds a degree in mathematics, physics, and chemistry from the Ecole Superieure de Physiques et Chimie Industrielles in France, and a master’s of science in chemical engineering from the University of California at Berkeley.